The study, published in the Journal of Molecular Medicine, was led by Alejandro Silva-Palacios, Alejandra María Zúñiga-Muñoz, and Cecilia Zazueta of the National Institute of Cardiology Ignacio Chávez in Mexico City, together with collaborators at the National Autonomous University of Mexico and Tecnológico de Monterrey. The researchers set out to test whether cannabidiol, commonly abbreviated as CBD, could protect the heart in an animal model that closely mimics the human condition. They induced HFpEF in mice by combining a high-fat diet with L-NAME, a compound that inhibits nitric oxide synthesis and drives the nitrosative stress considered central to the disease. Over eight weeks, the animals developed the hallmark features of HFpEF: cardiac fibrosis, diastolic dysfunction, and systemic metabolic and inflammatory disturbances. CBD was then administered subcutaneously every three days, a dosing interval chosen to maintain sustained exposure to the compound.

The results were nuanced but striking. CBD did not shrink the enlarged, hypertrophied hearts of the diseased animals; cardiac hypertrophy persisted despite treatment. However, the compound produced meaningful improvements where they mattered most for HFpEF patients. Treated animals showed reduced cardiac fibrosis, the stiffening scar tissue that prevents the heart muscle from relaxing, and their diastolic function improved measurably. The researchers assessed hemodynamic performance using invasive pressure-volume loop analysis, the gold standard for evaluating how the ventricle fills and ejects blood, and complemented these measurements with histological examination and markers of oxidative stress. The improvement in filling dynamics, rather than pumping strength, is precisely the kind of benefit that HFpEF patients need, since their hearts fail not because they pump too weakly but because they cannot relax enough to refill.

To understand how CBD achieved these effects, the team turned their attention to cellular senescence, the state in which cells stop dividing but refuse to die, instead lingering in tissues and secreting a toxic cocktail of inflammatory molecules. This senescence-associated secretory phenotype, or SASP, has emerged as a key driver of age-related diseases, and growing evidence links it to heart failure. In the HFpEF mice, senescent cells had accumulated in the heart, and circulating cytokine levels were elevated, consistent with a body-wide SASP-driven inflammatory state. CBD treatment markedly reduced the accumulation of these senescent cells and lowered systemic cytokine levels. The finding suggests that CBD may act as a partial senotherapeutic, clearing or calming the aged cells that fuel chronic inflammation in the failing heart.

The second major target was the NLRP3 inflammasome, a molecular machine inside immune and cardiac cells that, when activated, triggers caspase-1 and the release of potent proinflammatory cytokines such as interleukin-1 beta. NLRP3 activation has been implicated in cardiac remodeling, pulmonary artery changes, and general inflammation in HFpEF, and pharmacological inhibitors of this inflammasome have already shown benefit in mouse models of the disease. In the current study, CBD suppressed the NLRP3-mediated proinflammatory state, adding to a growing body of evidence that the compound can dampen inflammasome signaling. Previous work had shown that CBD inhibits NLRP3 activation in human monocytes through modulation of the P2X7 receptor, and that cannabinoids can attenuate cytokine storms driven by inflammasome pathways. The new findings extend this anti-inflammatory repertoire into the HFpEF setting.

Perhaps the most novel contribution of the study lies in its third focus: the mitochondria-endoplasmic reticulum contact sites, abbreviated MERCSs. These are microscopic junctions where the membranes of mitochondria, the cell’s power plants, and the endoplasmic reticulum, its protein-folding and calcium-storage factory, come into close apposition. At these contact points, the two organelles exchange calcium, lipids, and stress signals, coordinating everything from energy metabolism to cell death decisions. When MERCSs become excessive or disorganized, calcium overload and mitochondrial destabilization can activate the NLRP3 inflammasome, linking organelle architecture directly to inflammation. Using transmission electron microscopy, immunofluorescence, and RT-qPCR, the researchers found that in HFpEF the integrity of these contact sites was compromised, and that CBD treatment preserved inter-organelle distance and MERCSs structure.

This is the first demonstration, according to the authors, that CBD modulates MERCSs communication to regulate senescence and inflammation in HFpEF. The finding ties together threads that had previously run in parallel. Earlier work from the same group had shown that senotherapy in obese rats could act through a MERCSs/Nrf2 interaction, and other studies had established that disrupted sarcoplasmic reticulum-mitochondrial contacts underlie contractile dysfunction in atrial fibrillation, while enhanced tethering can trigger adaptive cardiac remodeling. In diabetes, hyperglycemia-driven promotion of mitochondria-associated endoplasmic reticulum membranes contributes to cardiomyopathy, and in aged hearts, defective calcium exchange between these organelles impairs function. By preserving the geometry of these junctions, CBD appears to prevent the calcium mishandling and mitochondrial stress that ignite inflammasome activation, thereby interrupting a vicious cycle in which organelle damage feeds inflammation, which in turn accelerates cellular aging.

The implications extend beyond the laboratory. HFpEF accounts for roughly half of all heart failure cases, and its burden is growing with the obesity and diabetes epidemics. Current treatment options remain limited, with recent trials of sodium-glucose cotransporter-2 inhibitors offering only partial benefit, and one such agent, empagliflozin, has been shown to protect against HFpEF partly by inhibiting a senescence-associated signaling axis. Pharmacological clearance of senescent cells has independently been shown to reduce inflammation, endothelial damage, and cardiac fibrosis in HFpEF models. The convergence of these findings suggests that targeting the biology of aging itself—senescent cells, their secretory products, and the organelle networks that control cellular stress—may be a viable therapeutic strategy for a disease that has defied conventional approaches.

CBD brings its own compelling profile to this strategy. Unlike tetrahydrocannabinol, it does not produce intoxication, and it has already been approved for certain forms of epilepsy, giving clinicians experience with its safety profile. Prior animal studies have shown that CBD attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory signaling in diabetic cardiomyopathy, prevents heart failure dysfunction through preservation of mitochondrial function and calcium handling, and promotes cardiomyocyte proliferation after myocardial infarction. A clinical trial, the ARCHER study, is currently evaluating CBD’s impact on myocardial recovery in patients with acute myocarditis. The new HFpEF findings add another potential indication to this expanding list, though the authors caution that the signaling pathways connecting MERCSs preservation to reduced senescence and inflammation still need to be fully characterized.

Important questions remain before CBD can be considered a treatment for HFpEF. The study was conducted in mice, and the dose, route, and timing of administration would need careful translation to humans. The failure to reduce hypertrophy suggests that CBD addresses some but not all of the disease’s pathological drivers, and it is unclear whether starting treatment earlier or later would change the outcome. Nevertheless, by identifying premature senescence, NLRP3-mediated inflammation, and MERCSs integrity as linked, druggable targets in HFpEF, the Mexican team has offered both a mechanistic explanation for CBD’s cardioprotective effects and a roadmap for the next generation of experiments. For a disease that affects millions and has resisted nearly every therapeutic attempt, the idea that a well-tolerated plant-derived compound might restore youthful communication between a cell’s organelles and quiet the inflammatory noise of aging tissue is a prospect worth watching closely.

Subject of Research: The cardioprotective effects of cannabidiol in heart failure with preserved ejection fraction through modulation of cellular senescence, NLRP3 inflammation, and mitochondria-endoplasmic reticulum contact sites.

Article Title: Prospective associations of premature senescence, inflammation, and MERCSs in the cardioprotective effect of CBD in HFpEF

Article References: Silva-Palacios, A., Zúñiga-Muñoz, A. M., Soria-Castro, E., Álvarez-León, E., García-Niño, W. R., Navarrete-Anastasio, G., Raza, D., Aparicio-Trejo, O. E., Ramírez-Carreto, R. J., Salas-Venegas, V., Chavarría, A., Maldonado-Ruíz, R. A., Alves-Figueiredo, H., García-Rivas, G., & Zazueta, C. (2026). Prospective associations of premature senescence, inflammation, and MERCSs in the cardioprotective effect of CBD in HFpEF. Journal of Molecular Medicine, 104(1), Article 109. https://doi.org/10.1007/s00109-026-02715-4

Image Credits: AI Generated

DOI: 10.1007/s00109-026-02715-4

Keywords: heart failure, HFpEF, cannabidiol, cellular senescence, SASP, NLRP3 inflammasome, MERCSs, mitochondria, endoplasmic reticulum, cardiac fibrosis, diastolic dysfunction, inflammation

The distinction between active relaxation and passive stiffness is central to understanding why the review’s cautious conclusion matters. Active relaxation is an energy-consuming process: after each heartbeat, calcium must be pumped back into the sarcoplasmic reticulum by SERCA2a, the sarco/endoplasmic reticulum calcium ATPase, and any residual calcium bound to the contractile proteins must be released so that cross-bridges detach and force declines. If calcium removal slows or myofilaments remain activated longer than they should, the ventricle begins to fill while it is still generating tension, and filling pressures rise. Passive stiffness, by contrast, is a property of the relaxed cell itself, determined largely by titin, the giant spring-like protein that spans from the Z-disc to the M-band of the sarcomere. Titin’s stiffness can be tuned by isoform switching, with the more compliant N2BA isoform giving way to the stiffer N2B isoform in some settings, and by phosphorylation of its elastic PEVK and N2B segments through kinases such as protein kinase A and protein kinase G. Hypophosphorylation of titin, oxidative modifications, and shifts in isoform ratio have all been proposed as mechanisms contributing to the elevated diastolic stiffness characteristic of HFpEF.

What makes the review’s framework particularly useful is its insistence on formal statistical testing of sex as a modifier. In experimental biology, it is common to report that females and males differ in some measured quantity, but a simple difference in a single endpoint does not establish that sex modifies the disease process. A true modifier effect requires a statistically significant interaction term, either sex by disease or sex by target, demonstrating that the effect of disease, or the response to an intervention, is itself different between the sexes. This is a much higher bar than demonstrating a baseline difference, and it is the appropriate standard when the clinical question is whether men and women should be classified or treated differently. By applying this standard systematically across the literature on calcium handling, myofilament function, titin, and mitochondrial bioenergetics, the authors converted a sprawling and often contradictory body of work into a much smaller set of defensible claims.

The result is striking in its sparseness. Among all the studies surveyed, the late sodium current emerged as the only active-relaxation-related cellular endpoint with a reported formal sex by disease interaction. The late sodium current is a small, sustained inward flow of sodium ions during the plateau phase of the cardiac action potential, and its pathological augmentation in disease states is thought to drive sodium and calcium overload through the sodium-calcium exchanger, contributing to diastolic tension and arrhythmogenic risk. The drug ranolazine, which suppresses the late current, has been tested clinically in the RALI-DHF trial for diastolic heart failure, making this target one of the few with a direct translational thread running from cellular electrophysiology to human intervention. Yet even here, the review notes that the reported sex interaction was electrophysiological rather than mechanical: the difference appeared in ionic current measurements, not in a demonstrated difference in how relaxation or stiffness responded. Without that mechanical link, the interaction remains an observation about membrane physiology rather than a guide to therapy.

The titin story illustrates a different kind of evidentiary gap. There is little doubt that titin modifications can change diastolic properties; interventions that alter titin phosphorylation or isoform expression have modified passive stiffness and filling in several HFpEF-like animal models, including models combining hypertension and metabolic stress such as the ZSF1 hybrid rat and models using L-NAME to induce nitric oxide synthase inhibition. Protein kinase G signaling, which phosphorylates titin and reduces its stiffness, has been a particularly attractive mechanistic target because it connects nitric oxide biology, cGMP signaling, and the phosphodiesterase pathways that have been explored pharmacologically in HFpEF. But the review’s systematic search found no experiment in which an independent laboratory replicated a sex-modified mechanical response to a titin-directed intervention. In other words, titin is clearly modifiable, and titin stiffness is clearly relevant to HFpEF, but the claim that women’s titin behaves differently from men’s titin in disease, in a way that would justify sex-specific treatment, has not been demonstrated under conditions that meet modern standards of rigor.

Mitochondrial bioenergetics and redox state occupy the connective position in this framework, and the review treats them accordingly. The energetic cost of relaxation is substantial: SERCA2a consumes a large fraction of the ATP generated by the cardiomyocyte, and any impairment of oxidative phosphorylation, NAD+ availability, or mitochondrial quality control can slow calcium reuptake and prolong contraction. Oxidative stress adds a second layer of vulnerability, because reactive oxygen species can modify ryanodine receptors, promote calcium leak, stiffen titin through oxidative cross-linking, and alter myofilament protein function. Pathways such as sirtuin 3, which depends on NAD+ and regulates mitochondrial protein acetylation, and calcium/calmodulin-dependent protein kinase II, which links calcium handling to oxidative stress, have each been implicated in diastolic dysfunction in experimental models. Interventions aimed at restoring NAD+ pools or reducing oxidative damage have improved diastolic phenotypes in some HFpEF-like settings. Yet here again, the review found no replicated demonstration that these bioenergetic interventions produce different mechanical benefits in females versus males, despite the plausible biological reasons to expect such differences, including known sex differences in mitochondrial function, estrogen-dependent regulation of energetics, and redox enzyme expression.

The confounding landscape surrounding this literature is unusually dense, and the review is careful to enumerate it. Findings varied with the animal model employed, the genetic strain, the age of the animals, their reproductive state, the specific disease driver used to induce the HFpEF phenotype, the stage of disease at which measurements were made, and the assay used to assess function. Each of these variables can plausibly interact with sex. Reproductive state is especially important in females, since estrogen status influences calcium handling proteins, mitochondrial enzymes, and titin phosphorylation, and ovariectomy versus intact status can change experimental outcomes. Age interacts with both sex and disease, because HFpEF is predominantly a disease of older adults and many animal models study young animals. Disease drivers matter because hypertension-driven, metabolic-driven, and anemia-driven HFpEF models produce overlapping but distinct cellular phenotypes. A sex difference observed in one combination of these variables may simply not generalize to another, which is precisely the pattern the review documents.

Human evidence, which would ideally anchor the field, is itself fragmented. Studies of ventricular tissue from patients with HFpEF have documented slowed active relaxation, elevated passive stiffness, and metabolic remodeling, including shifts in substrate utilization and mitochondrial protein expression. But these findings come from separate cohorts, often with small sample sizes, and the role of sex within each finding remains unresolved. Human myocardial tissue is difficult to obtain, typically available only from surgical procedures such as valve replacement or from transplant and autopsy material, and the underlying disease etiologies of donors vary widely. Direct comparisons of women and men using the same cellular assays on matched tissue are rare. This means that even the well-documented cellular abnormalities of HFpEF cannot currently be assigned a sex-specific prevalence or magnitude with confidence.

The review also draws a useful methodological distinction among the kinds of comparisons that would actually advance the field. One question is whether disease affects females and males differently, which requires comparing each sex against its own healthy control. A second question is whether a molecular target functions differently within diseased hearts of each sex, which requires testing the target’s contribution in both sexes under disease conditions. A third question is whether any observed difference is specific to disease rather than a baseline sex difference that exists independently of pathology. Many published studies conflate these questions, reporting sex differences without the appropriate controls to determine what kind of difference has been found. Prespecifying sex comparisons and linking them to a relevant functional endpoint, such as relaxation kinetics or passive force, would allow future studies to distinguish genuine modifier effects from incidental observations.

The clinical implications of this cautious conclusion deserve emphasis. If sex alone cannot define calcium-dominant or titin-dominant HFpEF endotypes, then treatment selection based on a patient’s sex would currently lack a mechanistic foundation. This does not mean sex is irrelevant to HFpEF; the epidemiological preponderance of women, differences in ventricular remodeling patterns, and known hormonal influences on cardiovascular physiology all remain real and clinically important. It means instead that the cellular mechanisms underlying any sex-related clinical differences have not been pinned down with the specificity needed to guide endotyping. The practical path forward suggested by the review is to treat sex as a hypothesis-generating variable to be tested in defined experimental and clinical settings, rather than as a classification tool. Until replicated, sex-stratified, mechanically anchored evidence accumulates, the heterogeneous reality of HFpEF, in which multiple cellular defects coexist and vary with context, remains the best available description of the disease for both women and men.

Subject of Research: Sex differences in cardiomyocyte relaxation mechanisms in heart failure with preserved ejection fraction

Article Title: Evaluating sex as a modifier of cardiomyocyte relaxation in heart failure with preserved ejection fraction: calcium handling, titin, and bioenergetics

Article References: Wang, B., & Dai, X.-C. (2026). Evaluating sex as a modifier of cardiomyocyte relaxation in heart failure with preserved ejection fraction: calcium handling, titin, and bioenergetics. Biology of Sex Differences. https://doi.org/10.1186/s13293-026-00993-8

Image Credits: AI Generated

DOI: 10.1186/s13293-026-00993-8

Keywords: HFpEF, cardiomyocyte relaxation, calcium handling, titin, passive stiffness, mitochondrial bioenergetics, sex differences, late sodium current, NAD+, diastolic dysfunction, heart failure, Biology of Sex Differences

The study drew on two prospective, multicenter Korean registries: the Korea Heart Failure Registry, which enrolled 3,200 patients hospitalized for acute heart failure at 24 tertiary centers between 2004 and 2009, and the Korean Acute Heart Failure Registry, which captured 5,625 patients across 10 tertiary centers between 2011 and 2014. After excluding 442 patients with missing body mass index or diabetes data, the researchers analyzed 8,383 individuals with a mean age of 68.2 years, 52 percent of whom were men. Importantly, the team applied an Asian-specific threshold for overweight, classifying patients as lean if their body mass index fell below 23 kilograms per square meter and overweight if it met or exceeded that value—a cutoff grounded in evidence that cardiometabolic risk rises at lower body weights in Asian populations than in Western ones. Roughly a third of the cohort had diabetes, and the patients were sorted into four groups: overweight non-diabetic, overweight diabetic, lean non-diabetic, and lean diabetic.

The baseline profiles of these groups told a striking story before any outcome data were even examined. Overweight patients without diabetes had the most favorable characteristics: they were younger, less likely to have ischemic heart disease, and displayed lower creatinine, C-reactive protein, and natriuretic peptide levels, along with better echocardiographic measures of cardiac function. At the opposite extreme, lean patients with diabetes carried the heaviest burden of disease, with more advanced heart failure symptoms, greater renal dysfunction, and a higher prevalence of ischemic etiology. That gradient—healthiest at the heavier, non-diabetic end of the spectrum and sickest at the lean, diabetic end—set the stage for outcome differences that were as dramatic as they were consistent.

During the index hospitalization, 5.3 percent of all patients died, with in-hospital mortality peaking at 6.9 percent among lean diabetic patients and falling as low as 4.2 percent among overweight diabetic patients. But it was the post-discharge picture that revealed the paradox in its sharpest form. Over one year of follow-up, 14.9 percent of patients died overall, yet the mortality gradient across the four groups was steep: 9.3 percent among overweight non-diabetic patients, 12.7 percent among overweight diabetic patients, 16.4 percent among lean non-diabetic patients, and a sobering 20.7 percent among lean diabetic patients. Diabetes alone raised the one-year mortality rate from 13.8 to 17.1 percent, but leanness exerted an even larger penalty, lifting mortality from 11.1 to 18.8 percent.

After multivariable adjustment for age, sex, systolic blood pressure, symptom severity, hemoglobin, renal function, ejection fraction, ischemic etiology, and other confounders, the survival advantage of overweight status remained statistically robust for one-year mortality. Overweight diabetic patients faced a 35 percent lower risk of death within a year compared with their lean diabetic counterparts, with an adjusted hazard ratio of 0.65 and a 95 percent confidence interval of 0.53 to 0.79. The same directional benefit appeared among overweight patients without diabetes. Critically, when the researchers tested for an interaction between body mass index and diabetes status, none was found—the protective association held with equal force whether or not a patient had diabetes. When body mass index was modeled as a continuous variable, each single-unit increase was associated with a 7 percent reduction in one-year mortality risk, and restricted cubic spline analysis revealed a smooth, monotonic decline in hazard across the entire observed range of body weight.

Intriguingly, the same pattern did not survive scrutiny for in-hospital mortality. Although the raw death rates favored heavier patients during the admission itself, the association weakened and lost statistical significance once the fully adjusted model accounted for the less favorable baseline profiles of lean patients—including their more advanced heart failure and greater comorbidity burden. This divergence suggests that body mass index carries greater prognostic weight over the months following discharge than during the acute phase, when illness severity and body composition may dominate short-term outcomes more than adiposity itself. In other words, the obesity paradox appears to be primarily a phenomenon of medium-term survival rather than of immediate peri-hospitalization risk.

The research team took considerable care to test whether their findings could be an artifact of statistical fragility. Sensitivity analyses using the World Health Organization overweight cutoff of 25 kilograms per square meter produced nearly identical results, with mortality falling monotonically across body mass index strata from 26.9 percent in the underweight range to just 7.0 percent among those with a body mass index of 30 or higher. Excluding patients with a body mass index below 20—who are most likely to suffer from cardiac cachexia, frailty, or severe malnutrition—did not erase the survival advantage of overweight status, arguing against reverse causality as the sole explanation. Registry-stratified analyses showed consistent associations in both cohorts, with no significant registry-by-body-mass-index interaction, and the pattern held across all three heart failure phenotypes: reduced, mildly reduced, and preserved ejection fraction. Only the smaller mid-range ejection fraction subgroup failed to reach statistical significance, most likely due to insufficient sample size.

Still, the investigators are careful to emphasize the limits of what an observational study can prove. Reverse causality—the idea that leanness reflects advanced disease rather than causing poor outcomes—cannot be dismissed entirely, and the registries lacked longitudinal weight trajectories, body composition data, nutritional markers, and measures of skeletal muscle mass that might distinguish protective adiposity from simply the absence of wasting. The cohort was also exclusively Korean, with a low mean body mass index of 23 kilograms per square meter, raising questions about generalizability to Western populations with very different body composition distributions. HbA1c data were missing in more than three-quarters of patients, diabetes type and duration were not captured, and the cohort predates the widespread use of sodium-glucose cotransporter-2 inhibitors, so the interplay between modern weight-lowering drugs and the paradox remains unresolved. The authors frame their conclusions explicitly as associations, not evidence of a causal protective effect of being overweight.

Yet the clinical implications are difficult to ignore, particularly at a moment when guideline-directed heart failure therapy increasingly includes drugs that cause weight loss. Sodium-glucose cotransporter-2 inhibitors can reduce body weight by 3 to 5 percent, and while trial-level evidence from DAPA-HF and EMPEROR-Reduced suggests these therapies benefit patients across the body mass spectrum without modifying the paradox, the new findings add urgency to the question of whether aggressive weight reduction is appropriate for lean patients with heart failure. Notably, a prespecified analysis of the STEP-HFpEF trial showed that semaglutide improved symptoms and function in overweight patients with preserved ejection fraction in proportion to the weight they lost—hinting that there may be a therapeutic sweet spot, a window of body weight beyond which the prognostic advantage of adiposity diminishes. For now, the message from Korea is unambiguous: among patients hospitalized with heart failure, low body weight—especially when combined with diabetes—identifies a strikingly vulnerable phenotype, and the obesity paradox is no respecter of diabetes status.

Subject of Research: The obesity paradox in heart failure patients with and without diabetes mellitus

Article Title: Obesity paradox in heart failure with and without diabetes mellitus: a retrospective cohort study

Article References: Kwon, O., Yoon, M., & Park, J. J. (2026). Obesity paradox in heart failure with and without diabetes mellitus: a retrospective cohort study. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-026-03007-0

Image Credits: AI Generated

DOI: 10.1007/s00392-026-03007-0

Keywords: obesity paradox, heart failure, diabetes mellitus, body mass index, mortality, KorHF, KorAHF, prognosis, HFrEF, HFpEF, SGLT2 inhibitors, cardiology